FDA review of new drugs through periodic paralysis

The US Food and Drug Administration (FDA) recently approved a rare neuromuscular diseases (periodic paralysis) a new drug to market. The new drug by the Taro Pharmaceuticals company with Keveyis brand name sales, the drug's chemical name dichlorobenzene two sulfonamides (dichlorphenamide). Professor, Department of Neurology University of Rochester Medical Center, Robert "Berch" Griggs, principal investigator of the clinical study of the drug. He said: "This is a very strange disease patients may wake up in the morning and found that has been completely paralyzed from the neck down in the course of a few hours, they again newly acquired normal motor function, etc.. they go to the doctor's office, they often is completely normal. "
Periodic paralysis is a rare disease in the United States there are about 5,000 patients. The disease is not fatal, it will not significantly shorten the life of, but because of this periodic loss of motor function and reduce the quality of life for themselves and their families a great deal of trouble. Some patients may last an entire month will not attack, it may only once a month paralyzed. While the other patients, their incidence of some higher frequency, short to only a fixed number of hours. Over time, many patients become weak and tired.
Almost 45 years ago, Professor Griggs first demonstration, acetazolamide for periodic paralysis have effective treatment portion. Recently, a team of researchers found that genetic factors periodic paralysis. In 2003, the US National Institutes of Health called for a nationwide research network organized by the other scientists, Professor Griggs composition, focusing on rare neurological diseases, such as periodic paralysis. In 2000, Professor Griggs and his colleagues showed in a study, dichlorobenzene two sulfa can effectively reduce the periodic paralysis attack and keep the patient's muscles strong.